Ultrasound-guided methotrexate injection for De Quervain disease of the wrist: what lies beyond the horizon?

De Quervain disease (DQVD) is one of the most common causes of lateral wrist pain and can lead to significant disability. The current case involves a right-handed, middle-aged, female patient with severe lateral wrist pain due to DQVD. Her pain was not responsive to oral non-steroidal anti-inflammatory drugs, rehabilitation, and repeated corticosteroid injections. Because she refused surgical intervention, we performed ultrasound-guided methotrexate injections (four times). After the injections, dramatic pain relief, functional improvement, and reduction of the thickness of the retinaculum and tendons in the first dorsal extensor compartment of the wrist were noted. This case report highlights the potential usefulness of ultrasound-guided methotrexate injection for recalcitrant DQVD of the wrist.

Introduction

De Quervain disease (DQVD) was first described by Fritz De Quervain in 1895 as a stenosing tenosynovitis of the abductor pollicis longus and extensor pollicis brevis tendons within the first dorsal extensor compartment of the wrist.1 It is a common cause of wrist pain and disability involving the dominant hand among middle-aged women.2 Most patients respond well to non-operative management, which includes immobilization of the thumb, non-steroidal anti-inflammatory drugs, physiotherapy, and local corticosteroid injection.3 Ultrasound-guided injection for DQVD helps in precisely targeting the involved tendons and reduces collateral damage to the neurovascular structures.4–6 The present case report aimed to demonstrate the potential usefulness of methotrexate in a patient with recalcitrant DQVD.

Consent for publication

We obtained written permission from the patient to publish this case report and the accompanying images.

Case description

The patient was a 38-year-old right-handed female farmer with hypothyroidism, who had been taking 100 mg l-thyroxine sodium (Eltroxin) once daily since March 2013 and she denied having systematic disease like hypertension, diabetes mellitus, rheumatoid arthritis, and other rheumatic diseases. In February 2014, she complained of right lateral wrist pain and was prescribed an oral non-steroidal anti-inflammatory drug under the diagnosis of De Quervain tenosynovitis. Because of incomplete pain relief after conservative treatment the patient was given corticosteroid injections by an orthopedic surgeon (three times) through palpation guidance combined with immobilization with a thumb spica cast, from May 2014, and her visual analog scale (VAS) was 1/10 after the last injection in August 2015. The patient did not receive ultrasound examination at that clinic due to inaccessibility of the machine. Her symptoms recurred in January 2016 with a VAS of 10/10. Surgical intervention was recommended to the patient, however, she refused surgery. She was referred to the Department of Physical Medicine at Tanta University Hospital. In our clinic, the physical findings revealed swelling and tenderness over the radial styloid with a positive Finkelstein’s test. The first metacarpal phalangeal joint appeared normal in range of motion and was not painful during palpation. Percussion of the radial styloid did not provoke the Tinel sign. We arranged a musculoskeletal ultrasound scan on February 10, 2016, which revealed marked thickening of the extensor retinaculum and swelling of the tendons inside the first dorsal wrist extensor compartment. There was no increase in power Doppler signals. There were no fibrous septa dividing the first extensor compartment (Figure 1A–C). After obtaining written consent, we injected 0.5 mL methotrexate (6.25 mg) with 0.5 mL mepivacaine (15 mg), four times starting from February 15, 2016, with an interval of 10 days between each injection under ultrasound guidance by using the in-plane approach, to target the short axis of the tendon sheath (Figure 2A). No adverse event was reported after the injections, and the patient reported gradual reduction of pain. Her VAS declined to 8/10, 7/10, 4/10, and 1/10 after each injection, respectively. By November 2016, the patient reported being pain free (VAS 0/10), and no more injections were administered. A follow-up ultrasound scan revealed a marked reduction in the size of the thickened retinaculum (from 3 to 1.2 mm) and swollen tendons (from 5.5 to 5.1 mm) in comparison with images taken before methotrexate injections (Figure 2B and C).

Figure 1

Ultrasound findings before methotrexate injection.

Notes: (A) Longitudinal scan of the tendons in the first dorsal extensor compartment of the wrist. (B) Transverse scan of the tendons in the first dorsal extensor compartment of the wrist. *The retinaculum. (C) Power Doppler examination of the tendons of the first dorsal extensor compartment of the wrist revealed no activity.

Figure 2

Ultrasound findings after methotrexate injection.

Notes: (A) Ultrasound-guided injection by using an in-plane short axis approach. Arrowheads indicate the needle. (B) Transverse scan of the tendons in the first dorsal extensor compartment of the wrist. *The retinaculum. (C) Longitudinal scan of tendons in the first dorsal extensor compartment of the wrist.

Discussion

DQVD affects 0.5% of working men and 1.3% of working women.7 Pregnancy, early motherhood, and postmenopausal status predispose women to the development of DQVD.8 Frequently, DQVD involves the dominant hand; however, involvement of the non-dominant hand is also encountered in clinical practice.9,10 The etiology is still unclear, and the risk factors include certain anatomic variations such as multiple tendons inside the first dorsal extensor compartment, presence of a fibrous septum, and mechanical overloading. The net result is inflammation of the tendon sheath, or thickening of the tendon and retinaculum. Microtears of the abductor pollicis longus and extensor pollicis brevis tendons may progress to complete rupture and complicate the treatment course. The underlying causes also influence the response to conservative treatments such as non-steroidal anti-inflammatory drugs, rehabilitation, and local steroid injection.8,11–13 Current literature suggests that corticosteroid injection is indicated in severe cases at the first visit and has a higher rate of remission than immobilization alone.14

Musculoskeletal ultrasound plays an important role in the detection of the anatomic variations of the first extensor compartment, including septa, tendon slips, and osseous ridges.15 It can reveal many pathological findings such as synovial hypertrophy, peritendinous hypervascularity, thickening of the retinaculum and tendon, and intratendinous microtears.8,9,16 Additionally, ultrasound-guided injection prevents intratendinous injection and reduces the risk of subsequent tear,17 precisely introduces the injectate to the affected region in case of an intracompartmental septum,18 and prevents the superficial radial nerve from the injury.19 In this case, ultrasound imaging clearly demonstrated thickening of the retinaculum, which might be the main factor leading to recurrence after overuse of the wrist.

Methotrexate, a disease modifying antirheumatic drug, is widely used in the treatment of rheumatoid arthritis. A key feature of intra-articular pathology of rheumatoid arthritis is hypertrophic synovium,20 which is commonly seen in recalcitrant stenosing tenosynovitis.8 The medication also can be safely administered for knee synovitis without preexisting rheumatic conditions.21 Therefore, the rationale of using methotrexate to treat DQVD is based on its potential effect to antagonize hypertrophic synovium. Methotrexate has anti-inflammatory and immunomodulatory effects owing to an elevated level of adenosine,20 which decreases pain by suppressing the production of substance P,22 prostaglandins, cytokines, and collagenases.23 Moreover, methotrexate has antifibrotic effects through the inhibition of fibroblasts.24 Injection of methotrexate has been widely used in the treatment of rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis and has shown promising effectiveness.25,26 Ultrasound-guided methotrexate injection can be safely administered at least every 7 days up to 8 times for the treatment of synovitis.27 Therefore, in this case, methotrexate not only resolved the inflammation inside the first dorsal extensor compartment of the wrist but also reduced hypertrophy of the retinaculum by reducing fibroblast activity. This dual effect is rarely seen with corticosteroid injection, which mainly contributes to reduction of inflammation at the injection site. However, the use of methotrexate may be associated with gastrointestinal upset, bone marrow toxicity, and hepatotoxicity. It is contraindicated in cases of hepatic and renal impairment; thus, the function of both the liver and kidney should be assessed before starting methotrexate therapy.23 Ultrasound guidance can prevent unwanted spreading of the methotrexate, to reduce the risk of tissue necrosis and demyelinating neuropathy of the superficial radial nerve. The main limitation of the study is its case number (n=1) and lack of a control. The beneficial effect of methotrexate could result from hydrodissection of the tendon. Therefore, a future randomized controlled trial should be conducted to investigate the true effectiveness of intrasheath methotrexate injection for DQVD.

Conclusion

Ultrasound-guided methotrexate injection could be a safe and effective method in the management of recalcitrant DQVD. Further large-scale studies are needed to compare its effectiveness with corticosteroid injection or surgical intervention.